Member Info for Bobbler

Just a minor point, if you have already or are considering investing in SAR shares, and in general any AIM share and are not already aware of the huge risks associated with these investments. Then I don’t believe you should even consider putting your money into this market.

TFF consolidation, we wouldn’t want the SP to bounce about :-)

Looking at the gov uk site, I wouldn’t be surprised if the application takes longer than some expect. I believe our compound could well fall into one of the stated categories.

Applications that need expert advice
For certain trials, we will seek advice from the Clinical Trials,

We may refer other applications for expert advice if we identify issues during the assessment process. Examples of trials where expert advice may be needed include first-in-human (FIH) trials with novel compounds where the:

mode of action involves a target that is connected to multiple signalling pathways (target with pleiotropic effects), e.g. leading to various physiological effects or targets that are ubiquitously expressed
compound acts (directly or indirectly) via a cascade system where there may be an amplification effect which might not be sufficiently controlled by a physiological feedback mechanism
compound acts (directly or indirectly) via the immune system with a target or mechanism of action which is novel or currently not well characterised
is novelty in the structure of the active substance e.g. a new type of engineered structural format such as those with enhanced receptor interaction as compared with the parent compound
level of expression and biological function of the target receptor may differ between healthy individuals and patients with the relevant disease
is insufficient available knowledge of the structure, tissue distribution, cell specificity, disease specificity, regulation, level of expression and biological function of the human target, including down-stream effects

https://www.gov.uk/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk#assessment-of-your-submission

That will be a bonus for us all if it means you’ll be gone and we no longer have to listen to your ****e :-)

https://www.fiercebiotech.com/biotech/lilly-spies-value-biotech-bear-market-snapping-hearing-loss-gene-therapy-player-akouos-487m

Colbalt, I agree the SP is significantly lower than its peak of last year. However it has risen 200% over the last 5 years, I doubt many pensions pots have gained 40% consistently for the past 5 years. Its all relative, property is very likely to drop in value in London over the next year or two. Does that make bricks and mortar a pile of worthless rubble??

Colbalt, if as you say, you've accepted reality, then why are you still here and one would have to assume invested?

Reminds me of a saying with references to headdress, sizes and donning.........

"A recent study has revealed that constantly moaning and whinging about a decision you, personally made to buy and hold a share or stock is a sign of boringness. It was also noted that this personality trait was common with those who constantly seek attention. Coupled with a superiority complex they often develop a ridiculous believe that they are more intelligent than the scientific BOD who run the company they have invested in. Sadly more often than not they personally couldn't run a bath, never a mind a PLC. However there is light at the end of this very dark tunnel, Professor Fooking Obvious of Frankfurt University, who has been studying Clown Syndrome for several years, stated all they have to do is grow a backbone and sell their shares."

HBD, apologies didn't see you had asked the same question!

Morning Stoney, is there a fixed duration / expiry date stated in the licence?

thanks in advance.

Kat, you might want to consider their ages, I don't think they want to play an indefinite long game as there on no pockets on a shroud.

Gilead paid $510 million in cash for YM BioSciences only drug Momelotinib. The drug, was reported to be an embarrassing dud in the clinic, and Sierra agreed to pay Gilead only $3 million in cash for the asset.

GSK have since purchased Sierra for $1.9 Billion, and in essence all they have is Momeltinib.
So Gilead must have misinterpreted the potential.

The article below explains why a return to SAR could be best for the molecule and all those involved in its advancement.

https://endpts.com/remember-momelotinib-gilead-unloads-rights-to-its-shelved-jak-inhibitor-for-token-3m-payment/

Good to see you back, you went very quiet during the last few days. Your presence tells me more good things to come.

Surfie, I watched my £30k investment drop to £8k and then peak at circa £380k. Be patient you state you’ve been invested a few months, that’s a very, very short time in pharma discovery stocks.

The absence of certain posters is very telling.

Groverlad - good to see you back mate. Always a good sign, the harder you try to bring the SP down, the higher it climbs.

Although most people consider you to be like a genital wart, I view you as a four leaf clover. Hang in there kid. Xx

Trading, so view changes depending on if selling or trying to buy

Denial is the first sign…….

“The Company believes the TYK2/JAK1 signalling pathway which it is pursuing offers potential for superior efficacy compared with agents, such as deucravacitinib, which block just one of the two kinases.”

Tim sounding very bullish.

SCH……sadly I don’t think it will help.
It must be hard work being negative about every investment one has……. Makes you feel blue.

More interesting, in my opinion is the fact the self proclaimed Professor of the English Language, who loves nothing more than correcting other posters grammatical errors. Has actually incorrectly spelt his own user name….. sorry to be so negative.